Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy.
about
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI ...Performance characteristics of combinations of host biomarkers to identify women with occult placental malaria: a case-control study from MalawiCombinations of host biomarkers predict mortality among Ugandan children with severe malaria: a retrospective case-control studyDetection of venous thromboembolism by proteomic serum biomarkers.Multimarker approach predicts adverse cardiovascular events in women evaluated for suspected ischemia: results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome EvaluationConcurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.Utility of salivary biomarkers for demonstrating acute myocardial infarction.Association of 25-hydroxyvitamin D deficiency with NT-pro BNP levels in patients with acute myocardial infarction: a cross-sectional analysis.NT-proBNP, C-reactive protein and soluble uPAR in a bi-ethnic male population: the SAfrEIC studyConsolidated and emerging inflammatory markers in coronary artery diseaseFunctional genomics applied to cardiovascular medicine.Relation between high-sensitivity C-reactive protein and coronary plaque components in patients with acute coronary syndrome: virtual histology-intravascular ultrasound analysis.Plasma ProBNP Is Not a Specific Marker for Transient Myocardial Ischemia.No Added Value of Novel Biomarkers in the Diagnostic Assessment of Patients Suspected of Acute Coronary Syndrome.The effect of changing diagnostic algorithms on acute myocardial infarction rates.Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis.Comparing serum levels of cardiac biomarkers in cancer patients receiving chemotherapy and subjects with chronic periodontitisBiomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study.Research translation: a new frontier for clinical laboratories.Ratio of preoperative atrial natriuretic peptide to brain natriuretic peptide predicts the outcome of the maze procedure in mitral valve disease.Usefulness of cardiac biomarker score for risk stratification in stable patients undergoing elective cardiac evaluation across glycemic status.Recent development in pharmacogenomics: from candidate genes to genome-wide association studies.New methods for improved evaluation of patients with suspected acute coronary syndrome in the emergency departmentPrognostic value of circulating chromogranin A levels in acute coronary syndromesEmerging families of biomarkers for coronary artery disease: inflammatory mediatorsBiomarkers in Acute Coronary Syndrome.Is adiponectin associated with acute myocardial infarction in Iranian non obese patients?Acute coronary syndromes: from the laboratory markers to the coronary vesselsIntegrating soluble biomarkers and imaging technologies in the identification of vulnerable atherosclerotic patients.A Comparison of Prognostic Value of the Levels of ProBNP and Troponin T in Patients with Acute Coronary Syndrome (ACS)Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes.Multi-marker strategies in heart failure: clinical and statistical approachesPoint-of-care testing in critical care: the clinician's point of view.Natriuretic peptides in heart failure: where we are, where we are going.Acute Kidney Injury: Diagnostic Approaches and ControversiesEvaluation of Cardiac Toxicity Biomarkers in Rats from Different Laboratories.Combined Assessments of Biochemical Markers and ST-Segment Resolution Provide Additional Prognostic Information for Patients With ST-Segment Elevation Myocardial Infarction.Measuring soluble CD40 ligand: it is a fancy prognostic biomarker in STEMI-patients?Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota Heart SurveyIdentification of protein biomarkers associated with cardiac ischemia by a proteomic approach.
P2860
Q24650933-CEDF93BE-AA9E-48E1-983F-BCDA114334C2Q28741606-3F0064C3-89A4-4FC0-89FB-3E6368B21604Q28742367-DFB631D7-CD5E-4922-8010-111D14ACBC02Q33288265-F8DF445F-6FCD-47AF-8853-61B2D5665264Q33610895-118C798D-C7D8-49E3-863A-99B8C05CC00FQ33691730-4F7DA8D7-35D7-497C-9CE1-7205875A22D3Q33936565-4DD8AC46-E84C-4590-B9B0-D845F9927B7EQ34101745-4D627BAC-8A54-48A6-B8BC-10457A049AECQ34629677-CB9B6E72-2A85-4FB6-A4BA-B4D2517E361EQ35019922-8426D5C8-4619-4014-839F-995C08465264Q35110769-430C31D8-FCE4-41CE-A5D8-95F029884454Q35214585-98FBB100-2BD4-4FB0-926C-78BAF0ED284AQ35609802-18C80BBD-A736-4AE8-845D-69DA6D588B67Q35692595-039E55FF-84F8-42E7-BC41-6D393633CCA7Q35786724-FA10BE1F-91FD-4E0F-B76A-45649D793313Q36089848-AAA71783-C2A1-4F6E-B25D-E918D595F610Q36243994-1C8BF7C7-689E-49A1-9B22-7FA5C92CFFB0Q36455014-393F1C21-44C2-4FCA-A1C1-3D1195AB275BQ36646180-5F96ED03-A5DB-45E6-9398-20E525C4C575Q36710754-B7AB3A65-10E5-457C-AC28-2580430D1183Q36810879-7B0E7BCF-DBB2-4721-AC39-280A1EC13E27Q36874335-C07DD63C-7726-4411-BC01-DD6040B50C90Q37009466-8AC5282F-27B0-439A-A529-785A751D66E9Q37090512-2BCA3699-8FC3-4DB5-90C7-8931B04B5E42Q37115819-B8582979-3782-4C8A-869C-20C3A3E32F9FQ37207294-1FA4BD47-0D05-497E-ADA0-3408EE2ACF6FQ37223566-62D8105F-BD2F-4BBC-AB43-48E30B8E7C9BQ37277926-066E751B-7F87-48B3-94B7-4A2B49918273Q37277958-CD6BAD38-9B6F-47CA-8882-669CCD1BCF2EQ37279802-B8DDDA73-E9CB-454C-9EA2-E2C70DFCB2BFQ37396582-7AEB1406-1456-48CF-A4BE-F8B76D86644CQ37468671-B3C16F25-BFE2-4733-A623-AF777EA887BAQ37742114-3B203BE2-7F71-4DF4-8351-A5B3D19D04E3Q37790310-41358072-BD84-437F-A1BB-9E11ACF77F8BQ39123320-0BED0CB5-003F-4965-AB74-72A5F907843BQ39379692-828A0C94-6518-4F80-9253-845CE8BE9BFDQ42122291-5F852DEA-C3EF-421F-A245-00B510285E35Q42370341-1A1DCF22-3181-4E02-841C-834070B5F543Q42380662-49BA74CE-4C0F-4F1C-AEE7-4C5015789F6BQ44801273-56D68F02-1519-4887-BF20-2D22FC6FD025
P2860
Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy.
@en
Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy.
@nl
type
label
Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy.
@en
Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy.
@nl
prefLabel
Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy.
@en
Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy.
@nl
P1433
P1476
Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy.
@en
P2093
David A Morrow
P304
P356
10.1161/01.CIR.0000078080.37974.D2
P407
P577
2003-07-01T00:00:00Z